Education
About Us
Working with TipRanks
Follow Us
Bayer AG (BAYRY)
OTHER OTC:BAYRY
Earnings Data
Report Date
May 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.68Last Year’s EPS
0.7Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced clear operational progress—delivery of raised guidance, improved launch momentum in Pharma, meaningful DSO-driven cost savings, and a reduced net financial debt position in 2025—against substantial legal and cashflow headwinds. Management articulated tangible growth drivers across Crop Science, Pharma and Consumer Health and concrete cost-savings milestones, but also disclosed large litigation provisions (EUR 11.8 billion liabilities), expected negative free cash flow in 2026 due to ~EUR 5 billion litigation-related payouts, projected net debt increase and significant product declines (notably Xarelto and Eylea). Given the mix of strong operational execution and material financial/legal risks that will weigh on near-term cash flow and balance-sheet metrics, the tone of the call is cautiously constructive but realistic about the challenges ahead.Company Guidance
Delivered Raised Guidance and Full-Year Results
Currency- and portfolio-adjusted group net sales of EUR 45.5 billion for 2025; group net sales grew ~1% year-over-year on a currency- and portfolio-adjusted basis. Core earnings per share (reported definition) of EUR 4.91 and group EBITDA before special items of EUR 9.7 billion. Free cash flow of EUR 2.1 billion (upper end of guidance).
Improved Balance Sheet Position in 2025
Net financial debt reduced to below EUR 30 billion at end of 2025 (helped by free cash flow and ~EUR 1.4 billion FX tailwind), and core financial result improved due to lower interest expenses and positive equity-result changes.
Dynamic Shared Ownership (DSO) Cost Savings and Productivity Gains
DSO delivered an additional EUR 700 million of cost reductions in 2025; total savings through DSO expected to reach EUR 2 billion by the end of the year. Organizational flattening: roughly half as many layers and management reduced by ~2/3 vs. program start, enabling faster product launches and increased agility.
Crop Science: Licensing Windfall and Strong Seed/Trait Performance
Licensing resolutions with Corteva contributed ~EUR 300 million to Q4 2025 corn performance and ~EUR 450 million expected to support soy in Q1 2026. Corn seeds & traits benefited from historically high North American acreage and strong global performance; core Crop Science growth outlook of 1%–4% in 2026 and expected EBITDA margin (before special items) of 20%–22%.
Robust Pharma Launch Momentum
Launch products (Nubeqa, Kerendia, Beyonttra, Lynkuet) showed strong momentum in 2025. Company expects Nubeqa and Kerendia to grow ~50% in 2026 (constant currency). Pipeline progress included 16 clinical programs advanced and five new approvals/key indications in 2025.
Consumer Health Resilience and Strategic Focus
Consumer Health delivered stable net sales year-over-year in 2025 despite softness in the U.S. and China. 2026 guidance anticipates net sales growth of 0%–4% (currency and portfolio adjusted) and EBITDA margin before special items of 22%–24%, driven by Road to Billion strategy, e-commerce and AI investments.
Operational Transformation Enabling Faster Time-to-Market
DSO and other reorganizations shortened time-to-market for new products (examples: record launch speeds in Pharmaceuticals and <1-year launch cycles cited for some Consumer Health products), supporting faster commercialization of innovations.
BAYRY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BAYRY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $7.95 | $8.42 | +5.95% |
Aug 06, 2025 | $8.02 | $7.26 | -9.45% |
May 13, 2025 | $6.68 | $6.90 | +3.29% |
Mar 05, 2025 | $6.17 | $6.57 | +6.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Bayer AG (BAYRY) report earnings?
Bayer AG (BAYRY) is schdueled to report earning on May 12, 2026, Before Open (Confirmed).
What is Bayer AG (BAYRY) earnings time?
Bayer AG (BAYRY) earnings time is at May 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BAYRY EPS forecast?
BAYRY EPS forecast for the fiscal quarter 2026 (Q1) is 0.68.